ClinicalTrials.gg
CompletedNCT00162279Updated Dec 6, 2010

The Study of Abatacept in Combination With Etanercept

A Phase 2 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-06.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
26th of 63
141 · median 119
Started
2000
with 1 other
Phase 2
9 of 63
1 open now
Registered
8th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 26th largest by enrollment, is one of 2 that started in 2000, is one of 9 in phase 2, and was the 8th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • All subjects who had completed the short term portion of IM101-101.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
141 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone

    Time frame: at 6 months

Secondary outcomes

  1. ACR 50 and 70 will be evaluated

    Time frame: at 6 months

07

Study locations

35 sites
  • Local Institution
    Huntsville, Alabama, United States
  • Local Institution
    La Jolla, California, United States
  • Local Institution
    Long Beach, California, United States
  • Local Institution
    Los Angeles, California, United States
  • Local Institution
    Palo Alto, California, United States
  • Local Institution
    San Francisco, California, United States
  • Local Institution
    Denver, Colorado, United States
  • Local Institution
    Ft. Lauderdale, Florida, United States
  • Local Institution
    Titusville, Florida, United States
  • Local Institution
    Rome, Georgia, United States
  • Local Institution
    Chicago, Illinois, United States
  • Local Institution
    Hagerstown, Maryland, United States
  • Local Institution
    Boston, Massachusetts, United States
  • Local Institution
    Springfield, Massachusetts, United States
  • Local Institution
    Duluth, Minnesota, United States
  • Local Institution
    Lincoln, Nebraska, United States
  • Local Institution
    New Brunswick, New Jersey, United States
  • Local Institution
    Los Alamos, New Mexico, United States
  • Local Institution
    Albany, New York, United States
  • Local Institution
    Mineola, New York, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Bismarck, North Dakota, United States
  • Local Institution
    Cincinnati, Ohio, United States
  • Local Institution
    Portland, Oregon, United States
  • Local Institution
    Duncansville, Pennsylvania, United States
  • Local Institution
    Norristown, Pennsylvania, United States
  • Local Institution
    Charleston, South Carolina, United States
  • Local Institution
    Knoxville, Tennessee, United States
  • Local Institution
    Austin, Texas, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Temple, Texas, United States
  • Local Institution
    Salt Lake City, Utah, United States
  • Local Institution
    Edmonds, Washington, United States
  • Local Institution
    Tacoma, Washington, United States
  • Local Institution
    Glendale, Wisconsin, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2000, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Oct 2000
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results delay requested
Sep 10, 2010
Last update
Dec 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00162279
First posted
Sep 13, 2005
Start date
Oct 2000
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Dec 6, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion